# Multiple Roles of Cannabinoids in the Olfactory System

**Authors:** Thomas Heinbockel, Edward A. Brown

PMC · DOI: 10.3390/brainsci16020190 · Brain Sciences · 2026-02-05

## TL;DR

This paper reviews how cannabinoids influence the olfactory system, linking internal states like hunger and stress to smell perception and behavior.

## Contribution

The paper provides a comprehensive synthesis of the endocannabinoid system's role in olfactory processing, neurodevelopment, and disease.

## Key findings

- Endocannabinoid signaling via CB1 receptors modulates synaptic transmission and sensory gain in the olfactory bulb.
- The endocannabinoid system influences olfactory neurodevelopment and adult neurogenesis through stem cell regulation.
- Dysfunction in endocannabinoid signaling is linked to olfactory impairments and neurological disorders.

## Abstract

The endocannabinoid system is a ubiquitous neuromodulatory network that links internal physiological state to neural circuit function across the brain. While its roles in memory, reward, pain, and motor control are well established, its contribution to olfactory processing has only recently gained attention. This review synthesizes the current knowledge on the anatomical, cellular, and functional interactions between the endocannabinoid system and the olfactory pathway, from the olfactory epithelium and main olfactory bulb to higher order cortical targets. We highlight how endocannabinoid signaling, primarily via cannabinoid receptor type 1 (CB1), shapes synaptic transmission within olfactory bulb microcircuits, modulates centrifugal feedback, and adjusts sensory gain in a state-dependent manner, particularly in relation to hunger, feeding behavior, stress, and reward. In addition, we review evidence that the endocannabinoid system regulates olfactory neurodevelopment and adult neurogenesis by influencing neural stem cell proliferation, migration, and integration into existing circuits. Emerging links between endocannabinoid signaling, olfactory dysfunction, neuropsychiatric disease, metabolic disorders, and neurodegeneration underscore the translational relevance of this system. We also discuss methodological challenges inherent to studying endocannabinoid signaling and outline future directions, including circuit-specific targeting and intranasal delivery strategies. Together, these findings position the olfactory system as a powerful and accessible model for understanding how endocannabinoids couple internal state to perception and behavior, with important implications for therapeutic development.

## Linked entities

- **Proteins:** CNR1 (cannabinoid receptor 1)
- **Chemicals:** cannabinoids (PubChem CID 9852188)

## Full-text entities

- **Genes:** COX5A (cytochrome c oxidase subunit 5A) [NCBI Gene 9377] {aka COX, COX-VA, MC4DN20, VA}, Cnr1 (cannabinoid receptor 1) [NCBI Gene 12801] {aka CB-R, CB1, CB1A, CB1B, CB1R}, Napepld (N-acyl phosphatidylethanolamine phospholipase D) [NCBI Gene 296757] {aka NAPE-PLD}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, Dagla (diacylglycerol lipase, alpha) [NCBI Gene 309207] {aka Nsddr}, FAAH (fatty acid amide hydrolase) [NCBI Gene 2166] {aka FAAH-1, FAAH1, PSAB}, TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442] {aka VR1}, Dagla (diacylglycerol lipase, alpha) [NCBI Gene 269060] {aka Nsddr}, Cnr2 (cannabinoid receptor 2) [NCBI Gene 12802] {aka CB-2, CB2, CB2-R}, FAAH [NCBI Gene 29347], CNR1 (cannabinoid receptor 1) [NCBI Gene 1268] {aka CANN6, CB-R, CB1, CB1A, CB1K5, CB1R}, TAC1 (tachykinin precursor 1) [NCBI Gene 6863] {aka Hs.2563, NK2, NKNA, NPK, TAC2}, Faah (fatty acid amide hydrolase) [NCBI Gene 14073], Mgll (monoglyceride lipase) [NCBI Gene 23945] {aka Magl, Mgl}
- **Diseases:** injury to (MESH:D014947), neurodegeneration (MESH:D019636), neuropsychiatric disease (MESH:D004194), long-term depression (MESH:D000088562), arthritis (MESH:D001168), inflammation (MESH:D007249), epilepsy (MESH:D004827), rheumatoid arthritis (MESH:D001172), ET (MESH:C536924), brain injury (MESH:D001930), Brain diseases (MESH:D001927), pain (MESH:D010146), dyslipidemia (MESH:D050171), brain damage (MESH:D001925), subarachnoid hemorrhage (MESH:D013345), neurological, metabolic, and psychiatric disorders (MESH:D001523), addiction (MESH:D019966), Social interaction impairment (MESH:C563663), bladder overactivity (MESH:D053201), ischemic lesions (MESH:D017202), attention deficit disorder (MESH:D001289), cancer (MESH:D009369), cytotoxicity (MESH:D064420), weight loss (MESH:D015431), psychological disorders (MESH:D000067073), anorexia (MESH:D000855), neuroinflammation (MESH:D000090862), schizophrenia (MESH:D012559), anxiety (MESH:D001007), type 2 diabetes (MESH:D003924), suicidal ideation (MESH:D001072), epileptiform bursting (MESH:D014277), mood disorders (MESH:D019964), neuropathic pain (MESH:D009437), nausea (MESH:D009325), depression (MESH:D003866), Obese (MESH:D009765), cachexia (MESH:D002100), stroke (MESH:D020521), anorexia nervosa (MESH:D000856), appetite and metabolic disorders (MESH:D001068), hypersensitivity (MESH:D004342), hypercapnia (MESH:D006935), metabolic disease (MESH:D008659), post-traumatic stress disorder (MESH:D013313), impairment of cognitive flexibility (MESH:D003072), squamous (MESH:D002294), olfactory dysfunction (MESH:D000857), head and neck squamous cell carcinoma (MESH:D000077195), uremic pruritus (MESH:D011537), bulimia nervosa (MESH:D052018), cartilage erosion (MESH:D002357), hypoxia (MESH:D000860), vomiting (MESH:D014839), analgesia (MESH:D000699)
- **Chemicals:** 1-AG (-), fat (MESH:D005223), VDM11 (MESH:C462953), URB-597 (MESH:C500528), ethanolamine (MESH:D019856), histamine (MESH:D006632), curcumin (MESH:D003474), BIA 10-2474 (MESH:C000612073), PE (MESH:C483858), 2-AG (MESH:C094503), palmitoylethanolamide (MESH:C005958), PUFA (MESH:D005231), glycerophospholipids (MESH:D020404), AM281 (MESH:C109925), K+ (MESH:D011188), N-acylethanolamine (MESH:C022203), Na+ (MESH:D012964), Rimonabant (MESH:D000077285), Bromodeoxyuridine (MESH:D001973), antisense oligonucleotides (MESH:D016376), AM3506 (MESH:C556520), prostaglandins (MESH:D011453), Delta9-THC (MESH:D013759), PIP2 (MESH:D019269), URB694 (MESH:C555899), fatty acid (MESH:D005227), WIN 55,212-2 (MESH:C070417), JZL184 (MESH:C534333), phospholipid (MESH:D010743), eicosapentaenoic acid (MESH:D015118), SKF38393 (MESH:D015647), capsaicin (MESH:D002211), N-acylphosphatidylethanolamine (MESH:C000609813), amitriptyline (MESH:D000639), arachidonic acid (MESH:D016718), lipid (MESH:D008055), Endocannabinoid (MESH:D063388), acetylcholine (MESH:D000109), noradrenaline (MESH:D009638), PF-04457845 (MESH:C560620), GABA (MESH:D005680), oleamide (MESH:C029407), oleoylethanolamide (MESH:C488250), dopamine (MESH:D004298), membrane lipids (MESH:D008563), diacylglycerol (MESH:D004075), AM251 (MESH:C103505), glutamate (MESH:D018698), Anandamide (MESH:C078814), glucose (MESH:D005947), 5-hydroxytryptamine (MESH:D012701), nitric oxide (MESH:D009569), sesamol (MESH:C025583), Cannabinoid (MESH:D002186), quinpirole (MESH:D019257), calcium (MESH:D002118), N-arachidonoyl phosphatidylethanolamines (MESH:C109143), Chloride (MESH:D002712)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Canis lupus familiaris (dog, subspecies) [taxon 9615], Homo sapiens (human, species) [taxon 9606], Xenopus laevis (African clawed frog, species) [taxon 8355], Cannabis sativa (species) [taxon 3483]
- **Cell lines:** /6 — Homo sapiens (Human), Tongue squamous cell carcinoma, Cancer cell line (CVCL_5985)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938660/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938660/full.md

## References

149 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938660/full.md

---
Source: https://tomesphere.com/paper/PMC12938660